Hepatic metastasis is a poor predictive marker for erlotinib in lung adenocarcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Hepatic metastasis is a poor predictive marker for erlotinib in lung adenocarcinoma

Published:2016-09 Issue: Volume:94 Page:20-22
ISSN:0306-9877
Container-title:Medical Hypotheses
language:en
Short-container-title:Medical Hypotheses

Author:

He Yayi,Wang Yan,Zhang Shijia,Ren Shengxiang,Li Jiayu,Zhou Caicun

Funder

Shanghai National Health and Family Planning Commission

Shanghai Shen Kang Hospital Development Center

Publisher

Elsevier BV

Subject

General Medicine

Reference36 articles.

1. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008;Ferlay;Int J Cancer,2010

2. Global cancer statistics;Jemal;CA Cancer J Clin,2011

3. Cancer statistics 2005;Jemal;CA Cancer J Clin,2005

4. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003;Pfister;J Clin Oncol,2004

5. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature;D’Addario;J Clin Oncol,2005

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Pathogenesis, Organ Metastasis, and Targeted Therapy for Non-Small-Cell Lung Cancer;Journal of Environmental Pathology, Toxicology and Oncology;2024

2. CalliSpheres® microsphere transarterial chemoembolization combined with 125I brachytherapy for patients with non–small‐cell lung cancer liver metastases;Frontiers in Oncology;2022-08-12

3. Mechanisms and Future of Non-Small Cell Lung Cancer Metastasis;Frontiers in Oncology;2020-11-11

4. Durable complete response after afatinib and crizotinib in an advanced non-small cell lung cancer patient with EGFR L861Q mutation and acquired MET amplification: a case report;Annals of Palliative Medicine;2020-09

5. An oasis in the desert of cancer chemotherapeutic resistance: The enlightenment from reciprocal crosstalk between signaling pathways of UPR and autophagy in cancers;Biomedicine & Pharmacotherapy;2017-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3